$2
Defective Drugs - Zantac Cancer
Case results reflect publicly available information reported by the listed law firms. They are not results obtained by ThatCarHitMe.com. Every case is unique and must be evaluated on its own facts. Prior results do not guarantee a similar outcome. The results shown are not necessarily representative of all results obtained by these firms. No representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers.
Case Details
GSK reached a $2.2 billion settlement to resolve approximately 80,000 U.S. lawsuits related to its heartburn medication, Zantac, which was linked to an increased risk of cancer.
Additional Notes
GSK denied wrongdoing but settled to avoid prolonged litigation. Lawsuits claimed Zantac (ranitidine) was linked to increased cancer risk due to NDMA formation when exposed to heat.